PRF Technologies Ltd.

Listed Company
PRFXCIK 0001801834NasdaqNon-AcceleratedPharmaceutical PreparationsL3ILFY ends Dec 31
Period
FY 2025
Revenue
$17.0K
Net Income
$-5.02M
Total Assets
$12.00M
Equity
$8.54M
Shares Out
830.6K
Op. Cash Flow
$-3.96M

Business

PAINREFORM LTD. is a specialty pharmaceutical and technology company focused on reformulating established therapeutics and delivering AI-driven solar analytics. It develops PRF-110, a proprietary extended‑release, oil‑based ropivacaine formulation for localized post‑surgical analgesia, and offers DeepSolar, an AI-powered software platform (MyDeepSolar) for PV system monitoring and optimization. The company operates two principal divisions: drug development (clinical trials, regulatory filings, manufacturing via CMOs) and DeepSolar software services. It sells through clinical and surgical channels, hospitals, ambulatory centers and via B2B and B2B2C routes to solar operators and homeowners in the U.S., Europe and other international markets.

Summary from filing dated 2025-04-07

Financials

Latest annual snapshot (FY2025, period end 2025-12-31). Full statement history unavailable for this entity.

Revenue$17.0K
Net income$-5.02M
Total assets$12.00M
Total liabilities$2.71M
Stockholders' equity$8.54M
Operating cash flow$-3.96M

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro